Join the 'Platelet Aggregation Inhibition' group to help and get support from people like you.
Platelet Aggregation Inhibition Blog
| Tweet |
Aspirin Equals Pricier Blood Thinner for Preventing Clots: Study
Posted 4 Jun 2013 by Drugs.com
TUESDAY, June 4 – Aspirin appears to be just as good as more expensive, more potent blood-thinning medication for preventing blood clots after hip replacement surgery, according to new research. People who get artificial hips are at risk of serious blood clots, such as deep vein thrombosis and pulmonary embolism, after the surgery. To prevent them, doctors usually prescribe blood-thinning (anticoagulant) medications, such as low-molecular-weight heparin, which is given by injection, or the newer drug, rivaroxaban (brand name Xarelto), a pill. But that old medicine-cabinet standby, aspirin, also has blood-thinning properties. And the Canadian researchers wondered if this simple, inexpensive drug could also prevent blood clots after a major surgery. They compared the drugs for four weeks, following 10 days of treatment with heparin immediately post-surgery. The investigators found the ... Read more
Related support groups: Aspirin, Ecotrin, Platelet Aggregation Inhibition, Bayer Aspirin, Bufferin, Low Dose ASA, ZORprin, Aspergum, Buffered Aspirin, Ascriptin Enteric, Easprin, St Joseph Aspirin, Minitabs, Acuprin 81, Buffex, Bayer Aspirin Regimen, Genacote, Sloprin, Bayer Plus, Genprin
Double-Dose Plavix Benefits Certain Patients, Study Finds
Posted 2 Sep 2010 by Drugs.com
WEDNESDAY, Sept. 1 – More isn't necessarily better when prescribing the two drugs commonly used to treat patients who are in danger of having a heart attack, Plavix (clopidogrel) and aspirin, a new study suggests. Two reports on the data find that high doses of Plavix are good for some patients, but not all, while high-dose aspirin is no better than a low dose for preventing new heart attacks, other cardiac problems, stroke and death. The findings suggest a need to assess the risks and benefits individually, experts say. Patients who are at high risk for heart attack and stroke and low risk for bleeding are going to do well on a higher dose of Plavix, said Dr. Gregg Stone, author of an editorial in The Lancet. "Patients who are at lower risk for atherosclerotic complications, but high risk for bleeding should be treated with a more conservative lower dose," added Stone, director of ... Read more
Related support groups: Aspirin, Plavix, Ecotrin, Platelet Aggregation Inhibition, Bayer Aspirin, Bufferin, Low Dose ASA, Aspergum, St Joseph Aspirin, Buffered Aspirin, Ascriptin Enteric, Easprin, ZORprin, Minitabs, Acuprin 81, Buffex, Zero-Order Release, Bayer Aspirin Regimen, Genacote, Bayer Plus
Research Sheds Light on Increased Blood Clot Risk
Posted 24 Jun 2010 by Drugs.com
THURSDAY, June 24 – In an effort to uncover why some people's blood platelets clump faster than others, a genetic analysis has turned up a specific grouping of overactive genes that seems to control the process. On the plus side, platelets are critical for fending off infections and healing wounds. On the down side, they can hasten heart disease, heart attacks and stroke, the study authors noted. The current finding regarding the genetic roots driving platelet behavior comes from what is believed to be the largest review of the human genetic code to date, according to co-senior study investigator Dr. Lewis Becker, a cardiologist with the Johns Hopkins University School of Medicine. "Our results give us a clear set of new molecular targets, the proteins produced from these genes, to develop tests that could help us identify people more at risk for blood clots and for whom certain ... Read more
Related support groups: Platelet Aggregation Inhibition
Newer Blood Thinner Beats Plavix for Bypass Patients
Posted 16 Mar 2010 by Drugs.com
TUESDAY, March 16 – In a trial comparing two anti-clotting drugs, patients given Brilinta before cardiac bypass surgery were less likely to die than those given Plavix, researchers found. Both drugs prevent platelets from clumping and forming clots, but Plavix, the more popular drug, has been linked to potentially dangerous side effects in cancer patients. In addition, some people don't metabolize it well, making it less effective. "We did see about a 50 percent reduction in mortality in these patients [who took Brilinta], but without any increase in bleeding complications," Dr. Claes Held, an associate professor of cardiology at the Uppsala Clinical Research Center at Uppsala University in Sweden and the study's lead researcher, said during an afternoon press conference Tuesday. "Ticagrelor (Brilinta) in this setting, with acute coronary syndrome patients with the potential need for ... Read more
Related support groups: Plavix, Acute Coronary Syndrome, Platelet Aggregation Inhibition, Acute Coronary Syndrome - Prophylaxis
Ask a Question
Further Information
Related Condition Support Groups
Cardiovascular Conditions and Disorders
